EAN 2021 | Future of secondary progressive MS diagnosis and treatment
Dana Horakova, MD, PhD, Charles University in Prague, Prague, Czech Republic, discusses the future of diagnosis and treatment of secondary progressive multiple sclerosis (MS). An improved understanding of the pathogenesis of MS has led to the development of anti-inflammatory drugs that aim to cross the closed blood-brain barrier. Dr Horakova discusses the optimistic future that these drugs present. This interview took place during the European Academy of Neurology 2021 congress.
Disclosures
Dana Horakova was supported by the Czech Ministry of Education project Progress Q27/LF1.
She also received compensation for travel, speaker honoraria and consultant fees from Biogen, Novartis, Merck, Bayer, Sanofi, Roche,
and Teva, as well as support for research activities from Biogen Idec.
